The ability to target Mi-2β and recover ISG and inflammatory signals by Z36-MP5 might be further evaluated for integration of combinational immunotherapy in patients with melanoma and other immune resistant cancers in future translational and clinical research. The gene discussed is CHD4; the disease is melanoma.